First Reported Case of Dissociative Symptoms Associated With Zuranolone Use in Peripartum Depression.

Peripartum depression is commonly observed in women during or after pregnancy. While selective serotonin reuptake inhibitors remain a mainstay of treatment, novel neurosteroid-based therapies such as brexanolone and zuranolone offer promising, rapid-acting alternatives.  We have reported the first known case of dissociative symptoms temporally associated with zuranolone use. A woman in her early 50s with a history of post-traumatic stress disorder (PTSD) and bipolar 1 disorder presented to the emergency department on the seventh day of zuranolone therapy, exhibiting profound disorientation, impaired autobiographical recall, unsteady gait, and communication difficulties. She had restarted zuranolone after discontinuing it earlier due to initial side effects, including dizziness and mood worsening. Her laboratory and imaging workup were unremarkable, and her symptoms resolved within 10 hours of discontinuation of zuranolone with supportive care alone. This case raises important concerns about the safety of neurosteroids in individuals with a history of trauma, particularly due to the potential overlap between GABAergic modulation and dissociative symptoms. Dysregulation of GABA